# Andrew Lewin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrew-lewin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,634 |
| Field | Diabetes Treatment and Management |
| h-index | 24 |
| i10-index | 43 |
| OpenAlex ID | https://openalex.org/A5103371371 |
| Works | 75 |

## Researcher papers

- [Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes](https://scholariq.org/papers/efficacy-of-liraglutide-for-weight-loss-among-patients-with-type-2-diabetes/)
- [Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)](https://scholariq.org/papers/efficacy-and-safety-of-the-human-glucagon-like-peptide-1-analog-liraglutide-in/)
- [Initiating Insulin Therapy in Type 2 Diabetes](https://scholariq.org/papers/initiating-insulin-therapy-in-type-2-diabetes/)
- [Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes](https://scholariq.org/papers/selective-aldosterone-blockade-with-eplerenone-reduces-albuminuria-in-patients/)
- [Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin](https://scholariq.org/papers/combination-of-empagliflozin-and-linagliptin-as-second-line-therapy-in-subjects/)
- [Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies](https://scholariq.org/papers/evaluation-of-efficacy-and-safety-of-the-glucagon-receptor-antagonist-ly2409021/)
- [Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes](https://scholariq.org/papers/initial-combination-of-empagliflozin-and-linagliptin-in-subjects-with-type-2/)
- [Plasma Renin Activity and Blood Pressure in Terminal Renal Failure](https://scholariq.org/papers/plasma-renin-activity-and-blood-pressure-in-terminal-renal-failure/)
- [Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals](https://scholariq.org/papers/treatment-of-high-risk-patients-with-ezetimibe-plus-simvastatin-co/)
- [Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives](https://scholariq.org/papers/influence-of-race-and-dietary-salt-on-the-antihypertensive-efficacy-of-an/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.